A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma Global Development
- 06 Jun 2023 Interim results (n=6; As of data cutoff 1 Dec 2022) assessing the safety, PK, and efficacy data for 125mg and 250mg doses of intravesical enfortumab vedotin in patients with non-muscle invasive bladder cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 26 Apr 2023 According to Seagen media release, an abstract (Abstract NO. 4596) including an interim results from this study will be present at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023, in Chicago.
- 19 Apr 2023 Trial design presented at the 114th Annual Meeting of the American Association for Cancer Research